Page 1 of 94
NR 565 Advanced Pharmacology Final
Exam 2026 | Latest Version | Complete
Q&A with Detailed Rationales
Table of Contents
Module 1: Pharmacokinetics and Pharmacodynamics (25 questions)
Module 2: Antimicrobial Therapy (25 questions)
Module 3: Cardiovascular Pharmacology (30 questions)
Module 4: Endocrine Pharmacology (25 questions)
Module 5: Central Nervous System Pharmacology (30 questions)
Module 6: Respiratory Pharmacology (15 questions)
Module 7: Gastrointestinal Pharmacology (15 questions)
Module 8: Renal and Genitourinary Pharmacology (15 questions)
Module 9: Oncology and Immunosuppressants (15 questions)
Module 10: Pain Management and Controlled Substances (20 questions)
Module 11: Pediatric and Geriatric Pharmacology (20 questions)
Module 12: Comprehensive Final Review (45 questions)
Total: 280 Questions with Detailed Rationales
Module 1: Pharmacokinetics and Pharmacodynamics
Quiz 1: A nurse practitioner is prescribing a medication that is a weak
acid. The patient has a urinary pH of 8. Which effect will this have on
drug excretion?
, Page 2 of 94
A) Increased excretion
B) Decreased excretion
C) No change in excretion
D) Complete reabsorption
Answer: A) Increased excretion
Rationale: Weak acids are ionized in alkaline urine (pH 8), which traps
them in the urine and increases excretion. Weak bases are excreted faster
in acidic urine (ion trapping).
Quiz 2: A patient with hepatic cirrhosis is prescribed a medication with
high first-pass metabolism. Which adjustment is most appropriate?
A) Increase the dose
B) Decrease the dose
C) Administer intravenously
D) Administer with food
Answer: B) Decrease the dose
Rationale: Hepatic cirrhosis reduces liver function, decreasing first-pass
metabolism and leading to increased bioavailability. Doses should be
reduced to prevent toxicity.
Quiz 3: A medication has a half-life of 12 hours. How many hours will it
take to reach steady state?
A) 24 hours
B) 36 hours
C) 48 hours
D) 60 hours
Answer: D) 60 hours
Rationale: Steady state is reached after approximately 4 to 5 half-lives.
12 hours × 5 = 60 hours.
Quiz 4: A patient develops a rash after starting a new antibiotic. This
reaction is classified as which type of adverse drug reaction?
A) Type I hypersensitivity
B) Type II hypersensitivity
, Page 3 of 94
C) Type III hypersensitivity
D) Type IV hypersensitivity
Answer: D) Type IV hypersensitivity
Rationale: Rashes from antibiotics are typically Type IV delayed
hypersensitivity reactions, mediated by T-cells. Type I is anaphylaxis;
Type II is cytotoxic; Type III is immune complex-mediated.
Quiz 5: A patient is prescribed a medication that is a CYP3A4 inducer.
Which effect will this have on co-administered medications metabolized
by CYP3A4?
A) Increased drug levels
B) Decreased drug levels
C) No effect
D) Increased toxicity
Answer: B) Decreased drug levels
Rationale: CYP3A4 inducers (e.g., rifampin, carbamazepine) increase
enzyme activity, leading to faster metabolism and decreased levels of
co-administered drugs metabolized by CYP3A4.
Quiz 6: A patient is prescribed a medication that is a CYP3A4 inhibitor.
Which effect will this have on co-administered medications metabolized
by CYP3A4?
A) Increased drug levels
B) Decreased drug levels
C) No effect
D) Decreased half-life
Answer: A) Increased drug levels
Rationale: CYP3A4 inhibitors (e.g., ketoconazole, grapefruit juice)
decrease enzyme activity, leading to slower metabolism and increased
levels of co-administered drugs, increasing risk of toxicity.
Quiz 7: A patient with chronic kidney disease (CKD) has an estimated
glomerular filtration rate (eGFR) of 25 mL/min. Which adjustment is
most appropriate for a medication primarily excreted renally?
, Page 4 of 94
A) Increase the dose
B) Decrease the dose or increase the interval
C) No adjustment needed
D) Administer intravenously
Answer: B) Decrease the dose or increase the interval
Rationale: Renal function is significantly reduced with eGFR less than
30 mL/min. Medications excreted renally require dose reduction or
extended dosing intervals to prevent accumulation and toxicity.
Quiz 8: A patient is prescribed a medication with a narrow therapeutic
index. Which monitoring is essential?
A) Drug levels
B) Blood pressure only
C) Weight only
D) No monitoring needed
Answer: A) Drug levels
Rationale: Narrow therapeutic index drugs (e.g., warfarin, digoxin,
lithium, phenytoin) have a small margin between therapeutic and toxic
doses. Drug level monitoring is essential to maintain therapeutic levels
and prevent toxicity.
Quiz 9: A patient is prescribed a medication that is highly protein-bound
(99 percent). Another highly protein-bound medication is added. Which
effect is expected?
A) Increased free drug levels of the first medication
B) Decreased free drug levels of the first medication
C) No change in drug levels
D) Decreased efficacy
Answer: A) Increased free drug levels of the first medication
Rationale: Highly protein-bound drugs compete for binding sites. When
two highly protein-bound drugs are given together, displacement
increases free (active) levels of both drugs, increasing risk of toxicity.
NR 565 Advanced Pharmacology Final
Exam 2026 | Latest Version | Complete
Q&A with Detailed Rationales
Table of Contents
Module 1: Pharmacokinetics and Pharmacodynamics (25 questions)
Module 2: Antimicrobial Therapy (25 questions)
Module 3: Cardiovascular Pharmacology (30 questions)
Module 4: Endocrine Pharmacology (25 questions)
Module 5: Central Nervous System Pharmacology (30 questions)
Module 6: Respiratory Pharmacology (15 questions)
Module 7: Gastrointestinal Pharmacology (15 questions)
Module 8: Renal and Genitourinary Pharmacology (15 questions)
Module 9: Oncology and Immunosuppressants (15 questions)
Module 10: Pain Management and Controlled Substances (20 questions)
Module 11: Pediatric and Geriatric Pharmacology (20 questions)
Module 12: Comprehensive Final Review (45 questions)
Total: 280 Questions with Detailed Rationales
Module 1: Pharmacokinetics and Pharmacodynamics
Quiz 1: A nurse practitioner is prescribing a medication that is a weak
acid. The patient has a urinary pH of 8. Which effect will this have on
drug excretion?
, Page 2 of 94
A) Increased excretion
B) Decreased excretion
C) No change in excretion
D) Complete reabsorption
Answer: A) Increased excretion
Rationale: Weak acids are ionized in alkaline urine (pH 8), which traps
them in the urine and increases excretion. Weak bases are excreted faster
in acidic urine (ion trapping).
Quiz 2: A patient with hepatic cirrhosis is prescribed a medication with
high first-pass metabolism. Which adjustment is most appropriate?
A) Increase the dose
B) Decrease the dose
C) Administer intravenously
D) Administer with food
Answer: B) Decrease the dose
Rationale: Hepatic cirrhosis reduces liver function, decreasing first-pass
metabolism and leading to increased bioavailability. Doses should be
reduced to prevent toxicity.
Quiz 3: A medication has a half-life of 12 hours. How many hours will it
take to reach steady state?
A) 24 hours
B) 36 hours
C) 48 hours
D) 60 hours
Answer: D) 60 hours
Rationale: Steady state is reached after approximately 4 to 5 half-lives.
12 hours × 5 = 60 hours.
Quiz 4: A patient develops a rash after starting a new antibiotic. This
reaction is classified as which type of adverse drug reaction?
A) Type I hypersensitivity
B) Type II hypersensitivity
, Page 3 of 94
C) Type III hypersensitivity
D) Type IV hypersensitivity
Answer: D) Type IV hypersensitivity
Rationale: Rashes from antibiotics are typically Type IV delayed
hypersensitivity reactions, mediated by T-cells. Type I is anaphylaxis;
Type II is cytotoxic; Type III is immune complex-mediated.
Quiz 5: A patient is prescribed a medication that is a CYP3A4 inducer.
Which effect will this have on co-administered medications metabolized
by CYP3A4?
A) Increased drug levels
B) Decreased drug levels
C) No effect
D) Increased toxicity
Answer: B) Decreased drug levels
Rationale: CYP3A4 inducers (e.g., rifampin, carbamazepine) increase
enzyme activity, leading to faster metabolism and decreased levels of
co-administered drugs metabolized by CYP3A4.
Quiz 6: A patient is prescribed a medication that is a CYP3A4 inhibitor.
Which effect will this have on co-administered medications metabolized
by CYP3A4?
A) Increased drug levels
B) Decreased drug levels
C) No effect
D) Decreased half-life
Answer: A) Increased drug levels
Rationale: CYP3A4 inhibitors (e.g., ketoconazole, grapefruit juice)
decrease enzyme activity, leading to slower metabolism and increased
levels of co-administered drugs, increasing risk of toxicity.
Quiz 7: A patient with chronic kidney disease (CKD) has an estimated
glomerular filtration rate (eGFR) of 25 mL/min. Which adjustment is
most appropriate for a medication primarily excreted renally?
, Page 4 of 94
A) Increase the dose
B) Decrease the dose or increase the interval
C) No adjustment needed
D) Administer intravenously
Answer: B) Decrease the dose or increase the interval
Rationale: Renal function is significantly reduced with eGFR less than
30 mL/min. Medications excreted renally require dose reduction or
extended dosing intervals to prevent accumulation and toxicity.
Quiz 8: A patient is prescribed a medication with a narrow therapeutic
index. Which monitoring is essential?
A) Drug levels
B) Blood pressure only
C) Weight only
D) No monitoring needed
Answer: A) Drug levels
Rationale: Narrow therapeutic index drugs (e.g., warfarin, digoxin,
lithium, phenytoin) have a small margin between therapeutic and toxic
doses. Drug level monitoring is essential to maintain therapeutic levels
and prevent toxicity.
Quiz 9: A patient is prescribed a medication that is highly protein-bound
(99 percent). Another highly protein-bound medication is added. Which
effect is expected?
A) Increased free drug levels of the first medication
B) Decreased free drug levels of the first medication
C) No change in drug levels
D) Decreased efficacy
Answer: A) Increased free drug levels of the first medication
Rationale: Highly protein-bound drugs compete for binding sites. When
two highly protein-bound drugs are given together, displacement
increases free (active) levels of both drugs, increasing risk of toxicity.
